Mindy Thomas, NP
Primary Care · Kansas City, MONPI 1578170692
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Lilly USA, LLC at 25.9% of the total. Reporting peaked in 2022 at $313 and has fallen 78.6% since, to $67 in 2024.
Across 33 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$159
- Novo Nordisk$113
- Sanofi Pasteur Inc.$62
- AstraZeneca$57
- AbbVie$42
- Merck$36
- plus $147 from 7 others
What the payments were for
- Food & beverage$615100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 8 | $159 |
| Novo Nordisk | 6 | $113 |
| Sanofi Pasteur Inc. | 3 | $62 |
| AstraZeneca | 4 | $57 |
| AbbVie | 2 | $42 |
| Merck | 2 | $36 |
| Amgen | 2 | $30 |
| Organon | 1 | $27 |
| Exeltis, USA Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Coopersurgical, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
How this compares
$615 in reported general payments places this provider in the 60th percentile of 106 primary care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metformin Hcl | 25 | $318 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 18 | $308 |
| Atorvastatin Calcium | 41 | $276 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $256 |
| Lisinopril | 23 | $148 |
| Metoprolol Succinate | 12 | $104 |
| Tizanidine Hcl | 17 | $88 |
| Losartan Potassium | 21 | $87 |
| Amlodipine Besylate | 21 | $74 |
| Allopurinol | 11 | $54 |
| Simvastatin | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Other primary care in Kansas City
- Avonne RosarioKansas City$3K
- Anne DaileyKansas City$549
- Myarka WilliamsKansas City$508
- Chandler PerryKansas City$268
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Katrina SelsorSparta$6K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Carol HarringtonIndependence$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.